FORMULARY WATCH

FDA actions

Why new lung cancer drug approval is important

By Christine Blank
FDA's approval last week of AstraZeneca's Iressa (gefitinib) for first-line treatment of patients with metastatic non-small cell lung cancer is an important tool in fighting the disease. Here's why

FDA warns about problems with Proglycem in infants

By Christine Blank
FDA is warning that diazoxide (Proglycem) for low blood sugar has caused pulmonary hypertension (high pressure in the blood vessels leading to the lungs) in infants and newborns. What to watch for

CONTINUING EDUCATION

MTM essentials for COPD Management: Part 2

This month's CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to assist pharmacists in understanding strategies for improving patient outcomes related to COPD management.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT32-KZV23.

The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php.
To review you registration page to ensure the data is up to date, or to register, go
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

FDA approves first ULS drug in 5 years

By Christine Blank
FDA approved Ipsen Biopharmaceuticals' supplemental Biologics License Application (sBLA) for abobotulinumtoxinA (Dysport) for the treatment of upper limb spasticity (ULS). Approval based on this rigorous development program

July 20, 2015